Methods for production of monoclonal antibodies with specificity for human lung cancer cells

J. D. Minna, F. Cuttitta, S. Rosen, P. A. Bunn, D. N. Carney, A. F. Gazdar, S. Krasnow

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

We have developed a screening strategy and technology to produce monoclonal antibodies with specificity for human lung cancer cells. Mice and rats were immunized with well-characterized tissue culture lines of human small cell lung cancer (SCLC), mouse myeloma x spleen hybrids formed by the technique of Kohler and Milstein, and the resulting culture fluids were screened for antibody binding phenotype using a radioimmunoassay. To facilitate testing large numbers of culture fluids, a 96-well, microtiter based, reusable, replicating device was designed. Using this, many hybridoma culture fluids were replica plated for antibody binding tests on a series of human target cell plates. Hybrids producing antibodies that reacted with the immunizing SCLC line and another independent SLCL line, but not with autologous B-lymphoblastoid cells derived from one of the patients, were identified, selected, and then repeatedly recloned using the same screening strategy. With this technology, hybridomas representing less than 0.5% of all hybrids generated could be isolated and stable antibody producing cultures derived. Such antibodies reacted with a panel of well-characterized SCLC lines and SCLC samples taken directly from patients but not with a variety of normal tissues. Using these antibodies we can demonstrate: tumor cell contamination of bone marrow specimens, marked heterogeneity of antigen expression on cells within individual SCLC lines and individual patients, and inhibition of clonal growth of SCLC lines in soft agarose assays. All of these findings have potential clinical and cell biologic application.

Original languageEnglish (US)
Pages (from-to)1058-1070
Number of pages13
JournalIn Vitro
Volume17
Issue number12
StatePublished - 1981

Fingerprint

Antibody Specificity
Small Cell Lung Carcinoma
Lung Neoplasms
Monoclonal Antibodies
Cells
Antibodies
Hybridomas
Fluids
Screening
Technology
Tissue culture
Bone Marrow Cells
Sepharose
Radioimmunoassay
Spleen
Rats
Tumors
Assays
Bone
Contamination

ASJC Scopus subject areas

  • Developmental Biology
  • Cell Biology
  • Clinical Biochemistry

Cite this

Minna, J. D., Cuttitta, F., Rosen, S., Bunn, P. A., Carney, D. N., Gazdar, A. F., & Krasnow, S. (1981). Methods for production of monoclonal antibodies with specificity for human lung cancer cells. In Vitro, 17(12), 1058-1070.

Methods for production of monoclonal antibodies with specificity for human lung cancer cells. / Minna, J. D.; Cuttitta, F.; Rosen, S.; Bunn, P. A.; Carney, D. N.; Gazdar, A. F.; Krasnow, S.

In: In Vitro, Vol. 17, No. 12, 1981, p. 1058-1070.

Research output: Contribution to journalArticle

Minna, JD, Cuttitta, F, Rosen, S, Bunn, PA, Carney, DN, Gazdar, AF & Krasnow, S 1981, 'Methods for production of monoclonal antibodies with specificity for human lung cancer cells', In Vitro, vol. 17, no. 12, pp. 1058-1070.
Minna JD, Cuttitta F, Rosen S, Bunn PA, Carney DN, Gazdar AF et al. Methods for production of monoclonal antibodies with specificity for human lung cancer cells. In Vitro. 1981;17(12):1058-1070.
Minna, J. D. ; Cuttitta, F. ; Rosen, S. ; Bunn, P. A. ; Carney, D. N. ; Gazdar, A. F. ; Krasnow, S. / Methods for production of monoclonal antibodies with specificity for human lung cancer cells. In: In Vitro. 1981 ; Vol. 17, No. 12. pp. 1058-1070.
@article{6d64cf8e64c54351b6f6c50bff74e1f8,
title = "Methods for production of monoclonal antibodies with specificity for human lung cancer cells",
abstract = "We have developed a screening strategy and technology to produce monoclonal antibodies with specificity for human lung cancer cells. Mice and rats were immunized with well-characterized tissue culture lines of human small cell lung cancer (SCLC), mouse myeloma x spleen hybrids formed by the technique of Kohler and Milstein, and the resulting culture fluids were screened for antibody binding phenotype using a radioimmunoassay. To facilitate testing large numbers of culture fluids, a 96-well, microtiter based, reusable, replicating device was designed. Using this, many hybridoma culture fluids were replica plated for antibody binding tests on a series of human target cell plates. Hybrids producing antibodies that reacted with the immunizing SCLC line and another independent SLCL line, but not with autologous B-lymphoblastoid cells derived from one of the patients, were identified, selected, and then repeatedly recloned using the same screening strategy. With this technology, hybridomas representing less than 0.5{\%} of all hybrids generated could be isolated and stable antibody producing cultures derived. Such antibodies reacted with a panel of well-characterized SCLC lines and SCLC samples taken directly from patients but not with a variety of normal tissues. Using these antibodies we can demonstrate: tumor cell contamination of bone marrow specimens, marked heterogeneity of antigen expression on cells within individual SCLC lines and individual patients, and inhibition of clonal growth of SCLC lines in soft agarose assays. All of these findings have potential clinical and cell biologic application.",
author = "Minna, {J. D.} and F. Cuttitta and S. Rosen and Bunn, {P. A.} and Carney, {D. N.} and Gazdar, {A. F.} and S. Krasnow",
year = "1981",
language = "English (US)",
volume = "17",
pages = "1058--1070",
journal = "In Vitro Cellular and Developmental Biology - Animal",
issn = "1071-2690",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Methods for production of monoclonal antibodies with specificity for human lung cancer cells

AU - Minna, J. D.

AU - Cuttitta, F.

AU - Rosen, S.

AU - Bunn, P. A.

AU - Carney, D. N.

AU - Gazdar, A. F.

AU - Krasnow, S.

PY - 1981

Y1 - 1981

N2 - We have developed a screening strategy and technology to produce monoclonal antibodies with specificity for human lung cancer cells. Mice and rats were immunized with well-characterized tissue culture lines of human small cell lung cancer (SCLC), mouse myeloma x spleen hybrids formed by the technique of Kohler and Milstein, and the resulting culture fluids were screened for antibody binding phenotype using a radioimmunoassay. To facilitate testing large numbers of culture fluids, a 96-well, microtiter based, reusable, replicating device was designed. Using this, many hybridoma culture fluids were replica plated for antibody binding tests on a series of human target cell plates. Hybrids producing antibodies that reacted with the immunizing SCLC line and another independent SLCL line, but not with autologous B-lymphoblastoid cells derived from one of the patients, were identified, selected, and then repeatedly recloned using the same screening strategy. With this technology, hybridomas representing less than 0.5% of all hybrids generated could be isolated and stable antibody producing cultures derived. Such antibodies reacted with a panel of well-characterized SCLC lines and SCLC samples taken directly from patients but not with a variety of normal tissues. Using these antibodies we can demonstrate: tumor cell contamination of bone marrow specimens, marked heterogeneity of antigen expression on cells within individual SCLC lines and individual patients, and inhibition of clonal growth of SCLC lines in soft agarose assays. All of these findings have potential clinical and cell biologic application.

AB - We have developed a screening strategy and technology to produce monoclonal antibodies with specificity for human lung cancer cells. Mice and rats were immunized with well-characterized tissue culture lines of human small cell lung cancer (SCLC), mouse myeloma x spleen hybrids formed by the technique of Kohler and Milstein, and the resulting culture fluids were screened for antibody binding phenotype using a radioimmunoassay. To facilitate testing large numbers of culture fluids, a 96-well, microtiter based, reusable, replicating device was designed. Using this, many hybridoma culture fluids were replica plated for antibody binding tests on a series of human target cell plates. Hybrids producing antibodies that reacted with the immunizing SCLC line and another independent SLCL line, but not with autologous B-lymphoblastoid cells derived from one of the patients, were identified, selected, and then repeatedly recloned using the same screening strategy. With this technology, hybridomas representing less than 0.5% of all hybrids generated could be isolated and stable antibody producing cultures derived. Such antibodies reacted with a panel of well-characterized SCLC lines and SCLC samples taken directly from patients but not with a variety of normal tissues. Using these antibodies we can demonstrate: tumor cell contamination of bone marrow specimens, marked heterogeneity of antigen expression on cells within individual SCLC lines and individual patients, and inhibition of clonal growth of SCLC lines in soft agarose assays. All of these findings have potential clinical and cell biologic application.

UR - http://www.scopus.com/inward/record.url?scp=0019768455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019768455&partnerID=8YFLogxK

M3 - Article

C2 - 6172365

AN - SCOPUS:0019768455

VL - 17

SP - 1058

EP - 1070

JO - In Vitro Cellular and Developmental Biology - Animal

JF - In Vitro Cellular and Developmental Biology - Animal

SN - 1071-2690

IS - 12

ER -